Heard on the Street: Moderna's cancer vaccine passed its first big test this past week. The bigger problem is that its stock is priced as if it has already passed them all.

Even after its latest sharp fall, the drugmaker's stock price assumes wild successes.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。